Adverse Drug Reaction Clinical Trial
Official title:
Pharmacists' Knowledge and Attitudes About ADRs Reporting and Pharmacovigilance Practice in Egyptian Hospitals
The present study has assessed the knowledge, attitude and practice of ADRs reporting among pharmacists, and the perceived factors that may influence reporting.
The practice and science of pharmacovigilance is described as the gathering, identification, monitoring, assessment, and prevention of adverse medication effects using pharmaceutical products. The term "pharmacovigilance" comes from the Greek words pharmakon (drug) and vigilare (vigilance) (monitor or keep an eye on). Pharmacovigilance (PV) is defined by the World Health Organization (WHO) as "the science and practices relating to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems". PV assesses the risk-benefit profile of medicines in order to improve patient safety. As a result, adverse drug reaction (ADR) reporting is the bedrock of any PV system, and early detection and reporting of ADRs to regional or national drug-regulatory bodies is important. ADRs are defined by the World Health Organization as an unpleasant and unexpected response to a medicine that occurs at levels usually employed in man for the prevention, diagnosis, or therapy of disease, or for the alteration of physiological function". Adverse drug reactions (ADRs) are major public health issues that have been linked to longer hospital stays and higher therapeutic costs. According to recent systematic reviews and meta-analyses of observational research, the rate of hospital admissions linked to ADRs is between 3-5 percent. A number of factors have been linked to HCPs, particularly pharmacists, reporting ADRs. Several studies have indicated reasons for not reporting observed ADRs, and pharmacists have been polled to determine the most important facilitators and barriers to spontaneous reporting. The seven deadly sins were coined by Inman and later defined by Lopez-Gonzalez et al., into professional and personal traits, as well as knowledge and attitudes toward reporting. Pharmacists from throughout the world have highlighted a number of barriers to reporting ADRs, including a lack of time, the inability to correlate an adverse event (AE) to a specific medicine, and the absence of readily available reporting forms . It has also emphasized the necessity of educational measures to encourage ADR reporting, such as awareness lectures and workshops. Egypt joined the WHO International Program for Drug Monitoring in 2001, but no concrete actions were done until 2009, when the Egyptian Pharmacovigilance Center was established (EPVC). Receiving ADR reports, detecting safety signals, sending frequent newsletters with pharmacovigilance (PV)-related updates, and conducting awareness training are only a few of EPVC's responsibilities. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT02559960 -
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
|
||
Completed |
NCT01946919 -
Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study
|
||
Recruiting |
NCT04154553 -
Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
|
||
Completed |
NCT01732302 -
Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients
|
N/A | |
Completed |
NCT02297126 -
A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program
|
N/A | |
Completed |
NCT03093818 -
PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions
|
N/A | |
Not yet recruiting |
NCT04568668 -
Evaluating ActionADE in Reducing Adverse Drug Reactions
|
N/A | |
Recruiting |
NCT02012504 -
Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients
|
Phase 0 | |
Completed |
NCT01872520 -
Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study
|
N/A | |
Completed |
NCT01467050 -
Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients
|
Phase 4 | |
Completed |
NCT01679964 -
Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study
|
Phase 4 | |
Completed |
NCT02094638 -
Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study
|
N/A | |
Recruiting |
NCT01906710 -
the Pharmacy Intervention Team Hospital-based (PITH) for People Study: Effect on Clinical and Economic Outcomes
|
N/A | |
Completed |
NCT02888834 -
Serious Adverse Drug Reaction and Their Preventability
|
N/A | |
Completed |
NCT02838212 -
Adverse Drug Reactions With Fatal Outcome
|
N/A | |
Completed |
NCT02159209 -
The Drug Induced Renal Injury Consortium
|
N/A | |
Completed |
NCT02134587 -
Educational Intervention in Pharmacovigilance for Hospital Health Professionals
|
N/A | |
Completed |
NCT04553107 -
Reducing Costs by Deprescribing Medications
|
N/A | |
Recruiting |
NCT06219720 -
The Texas Interprofessional Pharmacogenomics (IPGx)
|
||
Recruiting |
NCT05508763 -
Personalised Therapeutics @LUMC
|